Dr. Bullock is a recognized drug development scientist with clinical pharmacology and regulatory experience focused in the therapeutic areas of hematology/oncology and coagulation. She has unique insight in pediatric development, oncology dose-finding strategy and streamlining development for breakthrough therapies and accelerated approval. Bullock was a key leader in the scientific thinking for the basis of the U.S. Federal Drug Administration’s (FDA) acceptance of PK/PD development approaches for biosimilar products.
Prior to her role at Certara, Dr. Bullock was the clinical pharmacology team leader for the oncology/hematology team in the division of clinical pharmacology 5, which collaborated with the division of hematology products in the Center for Drug Evaluation and Research at the FDA. She also spent three years as a primary reviewer for investigational new drugs and new drug applications in the division of reproductive and urologic products and the division of drug oncology products.
Dr. Bullock received her doctor of pharmacy from Drake University and completed a clinical pharmacology drug development fellowship with the State University of New York at Buffalo and Novartis Pharmaceuticals.
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. As a result, it optimizes R&D productivity, commercial value and patient outcomes. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.